Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial

Clinical and Experimental Immunology

Volumn 177, Issue 2, 2014, Pages 544-553

  Malbran A ^a   Riedl, M ^b   Ritchie, B ^m   Smith, W B ^p   Yang, W ⁿ   Banerji, A ^c   Hebert J ^o   Gleich, G J ^e   Hurewitz, D ^f   Jacobson, K W ^g   Bernstein, J A ^h   Khan, D A ⁱ   Kirkpatrick, C H ^k   Resnick, D ^l   Li, H ^d   Fernandez Romero D S ^a   Lumry, W ^j  

^a HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d SHIRE   (United States)

^e UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^f Allergy Clinic of Tulsa   (United States)

^g Allergy and Asthma Research Group   (United States)

^h UNIVERSITY OF CINCINNATI   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j AARA Research Center   (United States)

^k UNIVERSITY OF COLORADO   (United States)

^l Department of Medicine   (United States)

^m UNIVERSITY OF ALBERTA   (Canada)

ⁿ Allergy and Asthma Research Centre   (Canada)

^o Centre de Recherche Appliquée en Allergie de Québec   (Canada)

^p ROYAL ADELAIDE HOSPITAL   (Australia)

more..

Author keywords

C1 inhibitor deficiency; FAST 1; Hereditary angioedema; Icatibant; OLE phase

Indexed keywords

ICATIBANT; PLACEBO;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LARYNX DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE;

BRADYKININ B2 RECEPTOR ANTAGONIST; C1-INHIBITOR DEFICIENCY; FAST-1; HEREDITARY ANGIOEDEMA; ICATIBANT; OLE PHASE;

ADULT; ANGIOEDEMAS, HEREDITARY; BRADYKININ; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, BRADYKININ; RETREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903976159     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12358     Document Type: Article

References (23)

1. Zuraw BL. Hereditary angioedema. N Engl J Med 2008; 359:1027-1036.
2. Weis M. Clinical review of hereditary angioedema: diagnosis and management. Postgrad Med 2009; 121:113-120.
3. Bork K, Harct J, Schicketanz K-H, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 2003; 163:1229-1235.
4. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130:692-697.
5. Winnewisser J, Rossi M, Spath P, Bürgi H. Type I hereditary angio-oedema. Variability of clinical presentation and course within two large kindreds. J Intern Med 1997; 241:39-46.
6. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Balt) 1992; 71:206-215.
7. Gompels A, Lock RJ, Abinun M etal. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139:379-394.
8. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Willson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010; 31:407-414.
9. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009; 19:147-151.
10. Tosi M. Molecular genetics of C1 inhibitor. Immunobiology 1998; 199:358-365.
11. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998; 351:1693-1697.
12. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007; 119:1497-1503.
13. Cicardi M, Banerji A, Bracho F etal. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363:532-541.
14. Lumry WR, Li HH, Levy RJ etal. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011; 107:529-537.
15. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001; 161:714-718.
16. Bork K, Meng G, Staubach P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005; 45:1774-1784.
17. Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy 2008; 63:751-757.
18. Aberer W, Maurer M, Reshef A etal. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy 2013; 69:305-314.
19. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119:267-274.
20. Cicardi M, Levy RJ, McNeil DL etal. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363:523-531.
21. Craig TJ, Levy RJ, Wasserman RL etal. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124:801-808.
22. Levy RJ, Lumry WR, McNeil DL etal. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104:523-529.
23. Wasserman RL, Levy RJ, Bewtra AK etal. Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks. Ann Allergy Asthma Immunol 2011; 106:62-68.